REGENXBIO Inc., a biotechnology company specializing in gene therapy, announced its participation in the Baird 2026 Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. These events will feature fireside chats on September 15 and 16, 2026, in New York, with live webcasts available on REGENXBIO's website. The company is advancing late-stage gene therapy treatments for rare and retinal diseases, aiming to improve healthcare delivery for millions. This participation highlights REGENXBIO's ongoing efforts to engage investors and showcase its pipeline progress.
Aurania Resources has begun a drilling program at the Thor's Valley gold project in Iceland, aiming to drill six holes totaling about 770 meters. The project has a history of high-grade gold mineralization, with previous drilling returning grades up ...
JP Morgan has maintained an 'overweight' rating on European banks, highlighting a favorable environment for growth despite early signs of interest rate changes. The sector benefits from ECB rates between 2% and 3%, strong lending momentum partly driv...
North Peak Resources has begun diamond drilling at its Prospect Mountain Mine Complex in Nevada to investigate refined magnetotelluric geophysical anomalies, focusing on a main sulphide target. Previous drilling in 2023 found high-grade zinc and silv...
Quimbaya Gold Inc. completed six drill holes totaling 2,927.9 meters at its Tahami Center project in Colombia, confirming the presence of a copper-molybdenum porphyry system as predicted by their exploration model. The drilling revealed potassic alte...
Hercules Capital (HTGC) is rated a hold due to its valuation rebounding to a 45% premium over book value. The company outperformed its sector peers by maintaining stable net investment income per share and achieving a 2.1% increase in net asset value...
